Highlights Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
4.66 ^USD	+3.79%		-1.48%	-28.85%

May. 13	Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call
May. 08	Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	May. 08	MT
Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'	Apr. 15	MT
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Posts Q4 Revenue $13.2M, vs. Street Est of $11.7M	Mar. 28	MT
Zevra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia	Mar. 26	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Zevra Therapeutics Shares Fall After FDA Extends Arimoclomol Review	Mar. 04	DJ
FDA Extends Review of Zevra's Arimoclomol by Three Months	Mar. 04	DJ
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	Jan. 11	DJ
Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C	Jan. 08	CI
Zevra Therapeutics, Inc.'s Equity Buyback announced on December 20, 2021, has expired.	Dec. 30	CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA	Dec. 27	DJ
Zevra Therapeutics Resubmits Arimoclomol New Drug Application to FDA	Dec. 27	MT
Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration	Dec. 27	CI
Zevra Therapeutics Completes Acer Acquisition	Nov. 20	MT
Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	Nov. 16	CI
Tranche Update on Zevra Therapeutics, Inc.'s Equity Buyback Plan announced on December 20, 2021.	Nov. 07	CI
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q3 Revenue $2.9M, vs. Street Est of $3.4M	Nov. 07	MT
Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023	23-09-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Highlights

Filters